Xilio Therapeutics, Inc. (XLO) shareholders
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 14,517,678 | 19.90% | 13G (passive) amendment | Dec 31, 2025 |
| Gilead Sciences Inc | 9,105,451 | 19.90% | 13G (passive) amendment | Dec 18, 2024 |
| Fhmlsp, L.P. Joint filing with Frazier Life Sciences Public Fund, L.P. (9.90%), Fhmlsp, L.L.C. (9.90%) | 8,141,017 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (9.90%), Steven A. Cohen (9.90%) | 8,000,000 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Yekaterina Chudnovsky Joint filing with Gkcc, LLC (15.90%) | 7,000,000 | 15.90% | 13G (passive) | Jun 7, 2024 |
| James N. Topper Joint filing with Patrick J. Heron (9.90%), Albert Cha (8.10%) and 4 more | 5,747,193 | 9.90% | 13G (passive) | Jun 5, 2025 |
| Coastlands Capital LLC Joint filing with Coastlands Capital LP (9.99%), Coastlands Capital Partners LP (9.99%) and 2 more | 5,346,069 | 9.99% | 13G (passive) | Dec 4, 2025 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (6.70%), Fhmlsp, L.L.C. (6.70%) | 4,676,472 | 6.70% | 13G (passive) amendment | Dec 31, 2025 |
| AbbVie Inc. | 4,347,826 | 9.00% | 13G (passive) | Feb 11, 2025 |
| StemPoint Capital LP Joint filing with StemPoint Capital Management GP LLC (7.20%), Michelle Ross (7.20%) | 4,000,000 | 7.20% | 13G (passive) | Sep 30, 2025 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (9.90%) | 1,142,862 | 9.90% | 13G (passive) | Mar 31, 2026 |
| BCLS II Equity Opportunities, LP | 664,021 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Orbimed Advisors LLC Joint filing with OrbiMed Capital GP X LLC (7.49%) | 642,000 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Michelle Ross Joint filing with StemPoint Capital LP (9.50%), StemPoint Capital Management GP LLC (9.50%) | 628,866 | 9.50% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XLO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | 11.48% | $6.36M | – | 0.38% |
| Gilead Sciences, Inc. | 650,389 | 11.25% | $6.23M | – | 0.38% |
| Orbimed Advisors LLC | 592,300 | 10.24% | $5.67M | New | 0.11% |
| Frazier Life Sciences Management, L.P. | 422,505 | 7.31% | $4.05M | – | 0.09% |
| Stonepine Capital Management, LLC | 225,994 | 3.91% | $2.17M | +161,832 | 1.22% |
| Vanguard Capital Management LLC | 178,517 | 3.09% | $1.71M | +54,857 | 0.00% |
| Sio Capital Management, LLC | 152,464 | 2.64% | $1.46M | – | 0.24% |
| Adage Capital Partners Gp, L.L.C. | 111,541 | 1.93% | $1.07M | New | 0.00% |
| Merck & Co., Inc. | 105,982 | 1.83% | $1.02M | – | 0.19% |
| Renaissance Technologies LLC | 64,153 | 1.11% | $614.59K | +14,587 | 0.00% |
| Morgan Stanley | 56,954 | 0.98% | $545.62K | −539 | 0.00% |
| Geode Capital Management, LLC | 39,055 | 0.68% | $374.17K | +1,858 | 0.00% |
| Citadel Advisors LLC | 25,950 | 0.45% | $248.60K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 22,594 | 0.39% | $216.45K | −5,881 | 0.00% |
| Bridgeway Capital Management, LLC | 17,544 | 0.30% | $168.07K | New | 0.00% |
| Two Sigma Investments, LP | 14,544 | 0.25% | $139.33K | New | 0.00% |
| Velan Capital Investment Management LP | 14,285 | 0.25% | $136.85K | – | 0.08% |
| Gsa Capital Partners Llp | 13,590 | 0.24% | $130.00K | −3,356 | 0.01% |
| State Street Corp | 13,311 | 0.23% | $127.52K | – | 0.00% |
| Prelude Capital Management, LLC | 11,600 | 0.20% | $111.13K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 26 | 3M | 58.9% | 10 / 4 | 4 / 7 | 1M | 0M |
| Q1 2026 | 24 | 3M | 45.3% | 7 / 7 | 8 / 19 | 1M | 1M |
| Q4 2025 | 37 | 3M | 49.1% | 11 / 4 | 5 / 9 | 1M | 0M |
| Q3 2025 | 36 | 2M | 27.2% | 4 / 6 | 4 / 3 | 0M | 0M |
| Q2 2025 | 35 | 2M | 29.4% | 5 / 4 | 11 / 5 | 0M | 0M |
| Q1 2025 | 35 | 2M | 27.8% | 6 / 8 | 7 / 6 | 0M | 0M |
| Q4 2024 | 35 | 2M | 31.9% | 9 / 6 | 5 / 5 | 1M | 0M |
| Q3 2024 | 33 | 1M | 19.7% | 6 / 8 | 4 / 4 | 0M | 0M |
| Q2 2024 | 32 | 1M | 17.9% | 7 / 9 | 6 / 6 | 0M | 0M |
| Q1 2024 | 31 | 1M | 16.0% | 6 / 4 | 5 / 8 | 0M | 0M |
| Q4 2023 | 34 | 1M | 20.5% | 6 / 8 | 4 / 3 | 0M | 0M |
| Q3 2023 | 31 | 1M | 19.6% | 2 / 5 | 7 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
10 funds held XLO in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XLO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 142,440 | 2.46% | $1.36M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 35,606 | 0.62% | $341.11K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 19,824 | 0.34% | $167.71K | 0.00% | May 31, 2026 |
| Ultra-Small Company Fund | 17,544 | 0.30% | $168.07K | 0.17% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 8,219 | 0.14% | $78.74K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 7,476 | 0.13% | $63.25K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 4,514 | 0.08% | $38.19K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,768 | 0.05% | $23.42K | 0.00% | May 31, 2026 |
| U.S. Vector Equity Portfolio | 1,507 | 0.03% | $13.73K | 0.00% | Jul 31, 2026 |
| Dimensional US Core Equity 1 ETF | 1,116 | 0.02% | $10.17K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 538 | 0.01% | $5.15K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 471 | 0.01% | $4.51K | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 254 | 0.00% | $2.31K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rene Russo | PRESIDENT AND CEO, Director | 325,422 | 5.63% | Jan 5, 2026 |
| Yariv Houvras | CHIEF MEDICAL OFFICER | – | – | Oct 2, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 | 0.43% | Jan 5, 2026 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 6,371 | 0.11% | Jan 5, 2026 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 33,250 | 0.58% | Jan 5, 2026 |
| Daniel J. Curran | Director | – | – | Jun 12, 2026 |
| Yuan Xu | Director | – | – | Jun 12, 2026 |
| Robert W. Ross | Director | – | – | Jun 12, 2026 |
| James Samuel Shannon | Director | 10,000 | 0.17% | Jun 12, 2026 |
| Aoife Brennan | Director | – | – | Jun 12, 2026 |
| Sara Bonstein | Director | – | – | Jun 12, 2026 |
| Akintunde Olatokumbo Bello | Director | – | – | Jun 12, 2026 |
| Cheryl R. Blanchard | Director | – | – | Apr 16, 2026 |
| Paul J. Clancy | Director | – | – | Jun 12, 2025 |
| Christina Rossi | Director | – | – | Jun 12, 2025 |
| Gilead Sciences, Inc. | 10% owner | 9,105,451 | 157.47% | Feb 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James Samuel Shannon Director | Mar 26, 2026 | Buy | +5,000 | $8.79 | $43.95K | 10,000 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 2, 2026 | Sale(10b5-1 plan) | −1,826 | $0.64 | $1.17K | 6,371 |
| Christopher James Frankenfield Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −7,030 | $0.64 | $4.50K | 24,766 |
| Katarina Luptakova CHIEF MEDICAL OFFICER | Jan 1, 2026 | Option exercise | +16,625 | – | – | 33,250 |
| Rene Russo PRESIDENT AND CEO, Director | Jan 1, 2026 | Option exercise | +44,250 | – | – | 325,422 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 1, 2026 | Option exercise | +5,000 | – | – | 8,197 |
| Christopher James Frankenfield Chief Financial Officer | Jan 1, 2026 | Option exercise | +19,375 | – | – | 31,796 |
| James Samuel Shannon Director | Jun 17, 2025 | Buy | +25,000 | $0.69 | $17.25K | 70,000 |
| Rene Russo PRESIDENT AND CEO, Director | Jun 16, 2025 | Buy | +36,289 | $0.68 | $24.68K | 281,172 |
| James Samuel Shannon Director | Jun 16, 2025 | Buy | +45,000 | $0.69 | $31.05K | 45,000 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 2, 2025 | Sale(10b5-1 plan) | −1,803 | $0.98 | $1.77K | 3,197 |
| Christopher James Frankenfield Chief Financial Officer | Jan 2, 2025 | Sale(10b5-1 plan) | −6,954 | $0.98 | $6.81K | 12,421 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 1, 2025 | Option exercise | +5,000 | – | – | 5,000 |
| Rene Russo PRESIDENT AND CEO, Director | Jan 1, 2025 | Option exercise | +44,250 | – | – | 244,883 |
| Katarina Luptakova CHIEF MEDICAL OFFICER | Jan 1, 2025 | Option exercise | +16,625 | – | – | 16,625 |
| Christopher James Frankenfield Chief Financial Officer | Jan 1, 2025 | Option exercise | +19,375 | – | – | 19,375 |
| Gilead Sciences, Inc. 10% owner | Dec 18, 2024 | Buy | +1,759,978 | $1.04 | $1.83M | 9,105,451 |
| Gilead Sciences, Inc. 10% owner | Apr 2, 2024 | Buy | +485,250 | $0.76 | $368.79K | 7,345,473 |
| Atlas Venture Fund XI, L.P. 10% owner | Feb 8, 2024 | Sale | −733 | $0.64 | $469 | 2,019,563 |
| Atlas Venture Fund XI, L.P. 10% owner | Feb 8, 2024 | Sale | −267 | $0.64 | $171 | 734,546 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 12, 2024 | Sale | −1,540 | $0.83 | $1.28K | 2,020,296 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 12, 2024 | Sale | −560 | $0.83 | $465 | 734,813 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 11, 2024 | Sale | −569 | $0.87 | $495 | 735,373 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 11, 2024 | Sale | −1,566 | $0.87 | $1.36K | 2,021,836 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 10, 2021 | Buy | +21,812 | $9.56 | $208.52K | 2,802,225 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 10, 2021 | Buy | +3,188 | $10.24 | $32.65K | 2,805,413 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 9, 2021 | Buy | +4,011 | $9.84 | $39.47K | 2,780,413 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 8, 2021 | Buy | +13,458 | $9.62 | $129.47K | 2,776,402 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Buy | +312,500 | $16.00 | $5.00M | 1,613,632 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Buy | +312,500 | $16.00 | $5.00M | 1,613,632 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Conversion | +756,472 | – | – | 756,472 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Conversion | +756,472 | – | – | 756,472 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Buy | +387,500 | $16.00 | $6.20M | 1,143,972 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Buy | +387,500 | $16.00 | $6.20M | 1,143,972 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +789,473 | – | – | 815,788 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +372,215 | – | – | 372,215 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +28,703 | – | – | 1,530,990 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +686,499 | – | – | 1,502,287 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +4,465 | – | – | 4,465 |
| Ltd FIL – | Oct 26, 2021 | Conversion | +218,705 | – | – | 218,705 |
| Takeda Ventures, Inc. 10% owner | Oct 26, 2021 | Conversion | +1,475,121 | – | – | 1,475,121 |
| City Capital Llc Bay 10% owner | Oct 26, 2021 | Buy | +312,500 | $16.00 | $5.00M | 1,129,490 |
| City Capital Llc Bay 10% owner | Oct 26, 2021 | Conversion | +665,696 | – | – | 665,696 |
| City Capital Llc Bay 10% owner | Oct 26, 2021 | Conversion | +151,294 | – | – | 816,990 |
| RiverVest Venture Fund IV, L.P. 10% owner | Oct 26, 2021 | Buy | +250,000 | $16.00 | $4.00M | 1,441,444 |
| RiverVest Venture Fund IV, L.P. 10% owner | Oct 26, 2021 | Conversion | +832,120 | – | – | 832,120 |
| RiverVest Venture Fund IV, L.P. 10% owner | Oct 26, 2021 | Conversion | +359,324 | – | – | 1,191,444 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Buy | +187,500 | $16.00 | $3.00M | 735,942 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Conversion | +1,372,998 | – | – | 1,399,313 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Conversion | +624,089 | – | – | 2,023,402 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Conversion | +548,442 | – | – | 548,442 |
| Alexandria Venture Investments, LLC 10% owner | Oct 26, 2021 | Conversion | +166,423 | – | – | 166,423 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xilio Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,621 shares on Oct 1, 2026 over the last 90 days.
See a number that looks wrong?